Genetic variation at the CYP2C locus and its association with torsemide biotransformation

Pharmacogenomics Journal

Volumn 7, Issue 3, 2007, Pages 200-211

  Vormfelde, S V ^a   Schirmer, M ^a   Toliat, M R ^b   Meineke, I ^a   Kirchheiner, J ^c   Nurnberg P ^b   Brockmoller J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; TORASEMIDE;

ADULT; ALLELE; ARTICLE; CARBOXYLATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TRANSFORMATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; LINEAR REGRESSION ANALYSIS; MALE; MOLECULAR EVOLUTION; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOLUNTEER;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; GENOTYPE; HAPLOTYPES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFONAMIDES;

EID: 34249075137     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500410     Document Type: Article

References (50)

1. Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
2. Kirchheiner J, Tsahuridu MWJ, Roots I, Brockmöller J. The CYP2C9 polymorphism: From enzyme kinetics to clinical dose recommendations. Personalized Med 2004; 1: 63-84.
3. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.
4. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
5. Totah RA, Rettie AE. Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77: 341-352.
6. Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448.
7. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8.
8. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473.
9. Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005; 18 1868-1875.
10. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-15422.
11. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005; 315: 1085-1090.
12. DeLozier TC, Tsao CC, Coulter SJ, Foley J, Bradbury JA, Zeldin DC et al. CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 2004; 310 845-854.
13. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77: 353-364.
14. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S et al. 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055-3057.
15. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001; 70: 175-182.
16. Sabeti PC, Reich DE, Higgins JM, Levine HZ, Richter DJ, Schaffner SF et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 2002; 419: 832-837.
17. Walsh EC, Sabeti P, Hutcheson HB, Fry B, Schaffner SF, de Bakker PI et al. Searching for signals of evolutionary selection in 168 genes related to immune function. Hum Genet 2006; 119: 92-102.
18. Schirmer M, Toliat MR, Haberl M, Suk A, Kamdem LK, Klein K et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet Genomics 2006; 16: 59-71.
19. Miners JO, Coulter S, Birkett DJ, Goldstein JA. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000; 10: 267-270.
20. Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995; 272: 1076-1081.
21. Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther 2004; 76: 557-566.
22. Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, Miners JO. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry 2004; 43: 7834-7842.
23. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101-109.
24. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
25. Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 1993; 43: 234-239.
26. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino Jr JS. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: Enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 2001; 41: 715-722.
27. Yasar U, Dahl ML, Christensen M, Eliasson E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002; 54: 183-185.
28. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773-780.
29. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
30. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 2005; 37: 84-89.
31. Walton R, Kimber M, Rockett K, Trafford C, Kwiatkowski D, Sirugo G. Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat Genet 2005; 37: 915-916; author reply 916.
32. Anonymous. The International HapMap Project. Nature 2003; 426 789-796.
33. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cYtochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-210.
34. Johnson DL, Lewis BC, Elliot DJ, Miners JO, Martin LL. Electrochemical characterisation of the human cytochrome P450 CYP2C9. Biochem Pharmacol 2005; 69: 1533-1541.
35. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299: 25-28.
36. Depre M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005; 61: 341-346.
37. Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 1996; 272 139-145.
38. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sorgel F, Klaassen T et al. Effect of propiverine on cytochrome P450 enzymes: A cocktail interaction study in healthy volunteers. Drug Metab Dispos 2005; 33: 1859-1866.
39. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.
40. Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 2005; 78: 529-539.
41. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
42. Lewontin RC. The interaction of selection and linkage. Ii. Optimum models. Genetics 1964; 50: 757-782.
43. Zeggini E, Barton A, Eyre S, Ward D, Ollier W, Worthington J et al. Characterisation of the genomic architecture of human chromosome 17q and evaluation of different methods for haplotype block definition. BMC Genet 2005; 6: 21.
44. Ding K, Zhou K, Zhang J, Knight J, Zhang X, Shen Y. The effect of haplotype-block definitions on inference of haplotype-block structure and htSNPs selection. Mol Biol Evol 2005; 22: 148-159.
45. Zhu X, Zhang S, Kan D, Cooper R. Haplotype block definition and its application. Pac Symp Biocomput 2004; 9: 152-163.
46. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
47. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68 978-989.
48. Sabeti PC, Walsh E, Schaffner SF, Varilly P, Fry B, Hutcheson HB et al. The case for selection at CCR5-Delta32. PLoS Biol 2005; 3: E378.
49. Engelhardt S, Meineke I, Brockmöller J. Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 831: 31-35.
50. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.